Advertisement

Volume 131, Issue 10

 

 

March 8, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Review series: strategies to improve GVL after allogeneic transplantation.  See the article by Soiffer et al.

GPVI signaling is compromised in newly formed platelets after acute thrombocytopenia in mice
Collagen normally activates platelets through glycoprotein VI (GPVI). Gupta and colleagues report that newly formed platelets have defective signaling through GPVI that normalizes after release into the circulation. They suggest that this may protect platelets from premature activation while they traverse the collagen-rich bone marrow microenvironment.


Disrupting CD147-RAP2 interaction abrogates erythrocyte invasion by Plasmodium falciparum
Zhang et al demonstrate that erythrocyte infection by the falciparum malaria parasite requires interaction between the parasite protein RAP2 and erythrocyte CD147 and that a CD147-blocking antibody prevents invasion. This suggests a potential novel target for preventing malarial infection.


NR4A1 and NR4A3 restrict HSC proliferation via reciprocal regulation of C/EBPα and inflammatory signaling
NR4A1 AND NR4A3 are nuclear receptors that were previously demonstrated to be suppressors of AML development. Freire and Conneely investigate their role in normal hematopoiesis and demonstrate that they maintain stem cell quiescence through modulation of both C/EPB transcriptional regulation and NF-κB signaling pathways.


A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium
In a Letter to Blood, Sun and colleagues report on a small phase 1 study combining low-dose azacitidine with chemotherapy in children with relapsed/refractory leukemia. They demonstrate encouraging results that correlate with specific methylation changes, supporting further study of this combination.


Introduction to a review series on strategies to improve GVL effects
Introduced with an editorial by Blood Associate Editor Robert Zeiser, this review series explores exciting new developments in treatments to enhance graft-versus-leukemia (GVL) effects in hematopoietic cell transplantation, including cellular therapies, antibody-based treatments, and drug-based approaches using tyrosine kinase inhibitors and checkpoint blockade.


The articles in this review series, "Strategies to Improve GVL Effects", include the following:

 

View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.